Daft Capital — 2025 Investments
1 investments dated 2025 · listed companies and verified rows first · show all
ARMR Sciencesarmrsciences.comin𝕏Aug 2025
ARMR Sciences is developing conjugate vaccines and biologic countermeasures, including its lead candidate ARMR-100, designed to bind fentanyl in the bloodstream and prevent overdose from synthetic drugs.
BiotechDeep TechHealthtechNew York, US
David Dowling(Founder)Shon Remich(Executive Officer)Jeffrey Hwang(Director)Nicholas Jacob(Executive Officer)Collin Gage(Executive Officer, Director)Kenneth Kohn(Director)
PartnerJon Dishotsky· solo GP
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.